BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22427209)

  • 1. Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib.
    Mir O; Coriat R; Boudou-Rouquette P; Ropert S; Durand JP; Cessot A; Mallet V; Sogni P; Chaussade S; Pol S; Goldwasser F
    Med Oncol; 2012 Dec; 29(4):2793-9. PubMed ID: 22427209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.
    Liu Y; Yue H; Xu S; Wang F; Ma N; Li K; Qiao L; Wang J
    Int J Clin Oncol; 2015 Oct; 20(5):952-9. PubMed ID: 25712158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis.
    Dhooge M; Coriat R; Mir O; Perkins G; Brezault C; Boudou-Rouquette P; Goldwasser F; Chaussade S
    Oncology; 2013; 84(1):32-8. PubMed ID: 23076239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2.
    Mir O; Coriat R; Dhooge M; Perkins G; Boudou-Rouquette P; Brezault C; Ropert S; Durand JP; Chaussade S; Goldwasser F
    Anticancer Drugs; 2012 Aug; 23(7):739-44. PubMed ID: 22700002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.
    Srimuninnimit V; Sriuranpong V; Suwanvecho S
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):255-60. PubMed ID: 24810940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.
    He MK; Zou RH; Li QJ; Zhou ZG; Shen JX; Zhang YF; Yu ZS; Xu L; Shi M
    Cardiovasc Intervent Radiol; 2018 May; 41(5):734-743. PubMed ID: 29327075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.
    Williet N; Dubreuil O; Boussaha T; Trouilloud I; Landi B; Housset M; Botti M; Rougier P; Belghiti J; Taieb J
    World J Gastroenterol; 2011 May; 17(17):2255-8. PubMed ID: 21633538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma.
    Lv Y; Liang R; Hu X; Liu Z; Liao X; Lin Y; Yuan C; Liao S; Li Q; Zhang J; Li Y
    Pharmazie; 2014 Oct; 69(10):759-63. PubMed ID: 25985566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib alone vs. sorafenib plus GEMOX as 1
    Assenat E; Pageaux GP; Thézenas S; Peron JM; Bécouarn Y; Seitz JF; Merle P; Blanc JF; Bouché O; Ramdani M; Poujol S; de Forges H; Ychou M; Boige V
    Br J Cancer; 2019 Apr; 120(9):896-902. PubMed ID: 30944458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.
    Taïeb J; Bonyhay L; Golli L; Ducreux M; Boleslawski E; Tigaud JM; de Baere T; Mansourbakht T; Delgado MA; Hannoun L; Poynard T; Boige V
    Cancer; 2003 Dec; 98(12):2664-70. PubMed ID: 14669287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study.
    Naqi N; Ahmad S; Murad S; Khattak J
    Hematol Oncol Stem Cell Ther; 2014 Mar; 7(1):27-31. PubMed ID: 24333135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study.
    Zaanan A; Williet N; Hebbar M; Dabakuyo TS; Fartoux L; Mansourbakht T; Dubreuil O; Rosmorduc O; Cattan S; Bonnetain F; Boige V; Taïeb J
    J Hepatol; 2013 Jan; 58(1):81-8. PubMed ID: 22989572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Shahda S; Loehrer PJ; Clark RS; Spittler AJ; Althouse SK; Chiorean EG
    Oncologist; 2016 Jun; 21(6):664-5. PubMed ID: 27256874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
    Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS
    J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
    J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.
    Zhu AX; Blaszkowsky LS; Ryan DP; Clark JW; Muzikansky A; Horgan K; Sheehan S; Hale KE; Enzinger PC; Bhargava P; Stuart K
    J Clin Oncol; 2006 Apr; 24(12):1898-903. PubMed ID: 16622265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience.
    Abdel-Rahman O; Abdelwahab M; Shaker M; Abdelwahab S; Elbassiony M; Ellithy M
    J Egypt Natl Canc Inst; 2014 Mar; 26(1):9-13. PubMed ID: 24565677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.
    Louafi S; Boige V; Ducreux M; Bonyhay L; Mansourbakht T; de Baere T; Asnacios A; Hannoun L; Poynard T; Taïeb J
    Cancer; 2007 Apr; 109(7):1384-90. PubMed ID: 17330837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
    Thomas MB; Garrett-Mayer E; Anis M; Anderton K; Bentz T; Edwards A; Brisendine A; Weiss G; Siegel AB; Bendell J; Baron A; Duddalwar V; El-Khoueiry A
    Oncology; 2018; 94(6):329-339. PubMed ID: 29719302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.